I aimed to define the efficacy of silodosin in treatment of lower urinary tract symptoms of men and form a background for a
nomogram for Turkish population.
Materials and Methods: Responses of treatment of 1600 male patients attending outpatient urology clinic with lower urinary
tract symtoms between March 2013 and March 2019 were evaluated retrospectively. The patients were between 41 and 97, mean
age of whom was 63,1±2,3 with serum total PSA level being under 4ng/dl and benign digital rectal examination findings, none of
them, getting any α-blocker for at least one month by the time of outpatient clinic attending. The patients who have been treated
with silodosin for 9 months due to benign prostatic hyperplasia (BPH) were evaluated retrospectively with their pretreatment
and posttretment results of Qmax (maximum flow rate), IPSS (International Prostate Symptom Score), IIEF (International Index of
Erectile Function) and PVR (postvoiding residue).
Results: Pretreatment and posttreatment basal PSA levels of the patients were 3.4±0.6 ng/ml and 3.9 ±0.7 respectively and it
was not statistically significant (p=0, 2). Pre and posttreatment mean IPSS values were 23, 8±2, 4 and 14 ,5±2, 5 respectively, being
statistically significant (p < 0,002)with mean Qmax values of 11, 7±2, 7ml/sec and 24, 3±2, 2ml/sec respectively (p < 0, 001). IIEF
scores were 35, 4±2, 2 and 39, 3±2, 4 being measured as pre and posttreatment values, respectively (p=0, 3). Pretreatment mean
PVR was 184, 4±7, 4ml/sec while the posttreatment mean value was 73, 4±21ml/sec, (p < 0, 02). The statistical analysis was made
according to paired t-test on parametric variables.
Conclusion: Prominent improvements with a 9-month silodosin treatment in values of Qmax, IPSS and PVR were statistically
significant, showing its efficacy but the changes in IIEF scores were not significant. This retrospective study showing the efficacy of
9-month silodosin for BPH is a promising one for future studies.